Effects of Alendronate and Calcitonin on Bone Mineral Density in Postmenopausal Osteoporotic Women. An Observational Study

被引：0
作者：
Miroslava Hejdova
Vladimir Palicka
Zdenek Kucera
Jiri Vlcek
机构：
[1] Charles University in Prague,Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove
[2] Charles University,Osteocentre, University Hospital
来源：
Pharmacy World and Science | 2005年 / 27卷
关键词：
Alendronate; Bone mineral density; Calcitonin; Czech Republic; Observational study; Postmenopausal osteoporosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: Alendronate and calcitonin are antiresorptive drugs that were used for the treatment of postmenopausal osteoporosis and were shown to increase bone mineral density (BMD). However, the effect of both drugs in daily clinical practice may differ from that observed in clinical trials.
引用
收藏
页码：149 / 153
页数：4
相关论文
共 90 条
[1]  
Chesnut CH(2000)Osteoporosis Prevention, Diagnosis, and Therapy March 27–29. 17 1-36
[2]  
Silverman S(2000)A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study Am J Med 109 267-76
[3]  
Andriano K(2000)Antifracture efficacy of antiresorptive treatments are related to changes in bone mineral density J Clin Endocrinol Metab 85 231-6
[4]  
Genant H(1999)Larger increase in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis Arthritis Rheum 42 1246-4
[5]  
Gimona A(1996)Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 312 1254-9
[6]  
Harris S(1997)Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications Bone 21 373-7
[7]  
Wasnich RD(2000)Alendronate and estrogen effects in postmenopausal women with low bone mineral density J Clin Endocrinol Metab 85 720-6
[8]  
Miller PD.(2002)Additive effect of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 985-92
[9]  
Hochberg M(2000)Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women J Clin Endocrinol Metab 85 3109-15
[10]  
Ross PD(2000)Response to alendronate in osteoporosis after previous treatment with etidronate Osteoporos Int 11 621-5
123456789